INTERCEPT Blood System for Platelets
Pathogen Inactivation Data: Leukocytes
The INTERCEPT Blood System for platelets has been shown to inactivate contaminating donor leukocytes including T-cells in platelet products. Various in vitro studies have demonstrated inhibition of leukocyte replication as well as inhibition of cytokine synthesis by leukocytes following photochemical treatment. The results of these studies are summarized below:
| Assay System | Extent of Inactivation | |
| In vitro | Limiting dilution assay | >5.4 log10 reduction of viable T-cells |
| DNA modification | Approximately one amotosalen adduct per 83 base pairs | |
| Polymerase chain reaction | Amplification inhibited by amotosalen – DNA adducts | |
| Cytokine synthesis | Elimination of IL-8, IL-1β synthesis during storage | |
| In vivo | Murine transfusion model | Prevention of TA-GVHD in a murine parent to F1 transfusion model |
Technical Data Sheets section page 6 of 7 
©
Cerus Corporation. All Rights Reserved.
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions
Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.
The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma.
Website design by NetPilot Web Solutions